An HIV-derived nucleoside therapy now treats rare genetic diseases by restoring mitochondrial DNA and improving muscle ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...

The 1980s painted a bleak picture for those diagnosed with HIV/AIDS. It was a death sentence shrouded in fear and uncertainty. Yet, during that bleak era, a beacon of hope ignited: antiretroviral ...

Despite highly effective HIV prevention drugs on the market, only a fraction of those at risk in the U.S. are taking them — or even know they're an option. It's called pre-exposure prophylaxis, or ...

Dr Robert Mutumba, the head of the Aids Control Programme at the Ministry of Health, told Daily Monitor that Ugandans are ...

The U.S. Food and Drug Administration has approved the drug lenacapavir as a twice-yearly injection to prevent HIV. The drug, called Yeztugo from company Gilead Sciences, was approved Wednesday based ...

Gilead Sciences’ pre-exposure prophylaxis (PrEP) formula of lenacapavir has been approved in the UK as a preventative option for HIV, offering patients a twice-yearly injection to reduce the risk of ...

A generation has passed since the world saw the peak in AIDS-related deaths. Those deaths — agonizing, from diseases or infections the body might otherwise fight off — sent loved ones into the streets ...

That experience moved Hurley to seek out PrEP, shorthand for preexposure prophylaxis. The antiretroviral medication greatly ...

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday. In clinical trials, the drug nearly eliminated HIV’s spread among ...

A generation has passed since the world saw the peak in AIDS-related deaths. Those deaths -- agonizing, from diseases or infections the body might otherwise fight off -- sent loved ones into the ...